Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Ther Drug Monit ; 45(6): 792-796, 2023 12 01.
Artigo em Inglês | MEDLINE | ID: mdl-37296505

RESUMO

BACKGROUND: Limited evidence from case reports suggests that coronavirus disease 2019 (COVID-19) vaccination may interact with the treatment outcomes of psychiatric medications. Apart from clozapine, reports on the effect of COVID-19 vaccination on other psychotropic agents are scarce. This study aimed to investigate the impact of COVID-19 vaccination on the plasma levels of different psychotropic drugs using therapeutic drug monitoring. METHODS: Plasma levels of psychotropic agents, including agomelatine, amisulpride, amitriptyline, escitalopram, fluoxetine, lamotrigine, mirtazapine, olanzapine, quetiapine, sertraline, trazodone, and venlafaxine, from inpatients with a broad spectrum of psychiatric diseases receiving COVID-19 vaccinations were collected at 2 medical centers between 08/2021 and 02/2022 under steady-state conditions before and after vaccination. Postvaccination changes were estimated as a percentage of baseline. RESULTS: Data from 16 patients who received COVID-19 vaccination were included. The largest changes in plasma levels were reported for quetiapine (+101.2%) and trazodone (-38.5%) in 1 and 3 patients, respectively, 1 day postvaccination compared with baseline levels. One week postvaccination, the plasma levels of fluoxetine (active moiety) and escitalopram increased by 31% and 24.9%, respectively. CONCLUSIONS: This study provides the first evidence of major changes in the plasma levels of escitalopram, fluoxetine, trazodone, and quetiapine after COVID-19 vaccination. When planning COVID-19 vaccination for patients treated with these medications, clinicians should monitor rapid changes in bioavailability and consider short-term dose adjustments to ensure safety.


Assuntos
COVID-19 , Trazodona , Humanos , Vacinas contra COVID-19 , Fluoxetina , SARS-CoV-2 , COVID-19/prevenção & controle , Escitalopram , Fumarato de Quetiapina , Estudos de Coortes , Psicotrópicos/uso terapêutico , Vacinação
2.
Vasa ; 45(2): 181-5, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-27058806

RESUMO

KEY MESSAGE: Based on two cases presented and our recently published experience, we think that for the majority of patients with central venous catheters misplaced in the vertebral artery, stent graft placement is the best bailout option.


Assuntos
Cateterismo Venoso Central/efeitos adversos , Cateterismo Venoso Central/instrumentação , Cateteres Venosos Centrais/efeitos adversos , Corpos Estranhos , Erros Médicos , Artéria Vertebral , Adulto , Idoso , Remoção de Dispositivo/instrumentação , Procedimentos Endovasculares/instrumentação , Feminino , Corpos Estranhos/diagnóstico por imagem , Corpos Estranhos/terapia , Humanos , Flebografia , Stents , Artéria Vertebral/diagnóstico por imagem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA